Bajaj Allianz grew the bet to 1.28% in Glenmark | Jun’20 qtr

glenmark logo

Glenmark Pharmaceuticals is one of the leading pharma companies in the world, manufacturing various medications and active drugs for a number of diseases, especially in the dermatology sector. From the quarter of Mar’20 to the quarter of Jun’20, the holdings through the promoters and public were constant at 46.62% and 53.38% respectively. The differences in the two mentioned quarters’ public shareholding data, are as follows:

Increase in shareholding % – Financial Institutions/ Banks grew the value from 2.99% to 3.16%. The number of shareholders with Individual share capital up to Rs. 2 Lacs widened from 1,49,335 to 3,17,577 and the holding rose from 9.59% to 13.28%. Non-Resident Indian (NRIs) went from 0.92% to 1.03%. Clearing Members expanded the stake from 0.20% to 1.67%. Qualified Institutional Buyers increased the parts from 2.61% to 2.70%. BAJAJ ALLIANZ LIFE INSURANCE COMPANY LTD grew the bet from 1.21% to 1.28%.

Decrease in shareholding % – Mutual Funds lowered the stakes from 3.74% to 2.36%. HDFC TRUSTEE COMPANY LTD reduced the bet from 3.19% to 2.33%. Foreign Portfolio Investors reported a decrease in value from 28.51% to 23.40%. HSBC POOLED INVESTMENT FUND – HSBC POOLED ASIA PAC went from 3.29% to 2.34%. Individuals with share capital in excess than Rs. 2 Lacs decremented the parts from 3.47% to 3.31%.

Identical shareholding % in both the quarters- Alternate Investment Funds at 0.01%. LIFE INSURANCE CORPORATION OF INDIA at 1.75%. Central Government/ State Government(s)/ President of India at 0.00%. ASHISH DHAWAN at 1.24%. Trusts at 0.35%. HDFC LIFE INSURANCE COMPANY LIMITED at 1.28%.

Shareholders, which might have exited the pattern or dipped below 1.00% in June quarter (with their March values)– FRANKLIN TEMPLETON INVESTMENT FUNDS at 1.53%. HSBC GLOBAL INVESTMENT FUNDS – ASIA EX JAPAN EQUITY at 1.06%. NTASIAN EMERGING LEADERS MASTER FUND at 1.01%.

The total number of public shareholders enlarged from 1,54,619 to 3,24,372.

LEAVE A REPLY

Please enter your comment!
Please enter your name here